Patents Assigned to Proscan RX Pharma
  • Publication number: 20110189093
    Abstract: Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: April 14, 2009
    Publication date: August 4, 2011
    Applicant: PROSCAN RX PHARMA
    Inventors: Serge Moffett, Dominic Melancon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • Patent number: 7811564
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: October 12, 2010
    Assignee: Proscan RX Pharma
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
  • Publication number: 20090131277
    Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Application
    Filed: April 19, 2005
    Publication date: May 21, 2009
    Applicant: PROSCAN RX PHARMA
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett